139 related articles for article (PubMed ID: 36604860)
1. Alectinib-induced hemolytic anemia.
Lee CS; Sullivan K
J Oncol Pharm Pract; 2023 Jul; 29(5):1251-1254. PubMed ID: 36604860
[TBL] [Abstract][Full Text] [Related]
2. Successful Treatment with Brigatinib after Alectinib-Induced Hemolytic Anemia in Patients with Metastatic Lung Adenocarcinoma-A Case Series.
El Sayed R; Tehfe M; Blais N
Curr Oncol; 2022 Dec; 30(1):518-528. PubMed ID: 36661690
[TBL] [Abstract][Full Text] [Related]
3. Successful alectinib desensitization in a patient with anaplastic lymphoma kinase-positive adenocarcinoma of the lung and alectinib-induced drug rash.
Anderson BE; Luczak TS; Ries LM; Hoefs GE; Silva-Benedict AC
J Oncol Pharm Pract; 2020 Dec; 26(8):2028-2030. PubMed ID: 32476587
[TBL] [Abstract][Full Text] [Related]
4. Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.
Goto Y; Yamamoto N; Masters ET; Kikkawa H; Mardekian J; Wiltshire R; Togo K; Ohe Y
Adv Ther; 2020 Jul; 37(7):3311-3323. PubMed ID: 32472430
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of lorlatinib after alectinib-induced interstitial lung disease in a patient with anaplastic lymphoma kinase-positive non-small cell lung cancer: a case report.
Kashizaki F; Tanaka A; Sekido Y
J Med Case Rep; 2022 Aug; 16(1):316. PubMed ID: 35999557
[TBL] [Abstract][Full Text] [Related]
6. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study.
Zhou C; Kim SW; Reungwetwattana T; Zhou J; Zhang Y; He J; Yang JJ; Cheng Y; Lee SH; Bu L; Xu T; Yang L; Wang C; Liu T; Morcos PN; Lu Y; Zhang L
Lancet Respir Med; 2019 May; 7(5):437-446. PubMed ID: 30981696
[TBL] [Abstract][Full Text] [Related]
7. ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib.
Kim ES; Barlesi F; Mok T; Ahn MJ; Shen J; Zhang P; Ou SI
Future Oncol; 2021 May; 17(14):1709-1719. PubMed ID: 33569983
[TBL] [Abstract][Full Text] [Related]
8. Alectinib: A Review in Advanced, ALK-Positive NSCLC.
Paik J; Dhillon S
Drugs; 2018 Aug; 78(12):1247-1257. PubMed ID: 30030733
[TBL] [Abstract][Full Text] [Related]
9. Successful oral desensitization against skin rash induced by alectinib in a patient with anaplastic lymphoma kinase-positive lung adenocarcinoma: A case report.
Shirasawa M; Kubotaa M; Harada S; Niwa H; Kusuhara S; Kasajima M; Hiyoshi Y; Ishihara M; Igawa S; Masuda N
Lung Cancer; 2016 Sep; 99():66-8. PubMed ID: 27565916
[TBL] [Abstract][Full Text] [Related]
10. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
Hida T; Nokihara H; Kondo M; Kim YH; Azuma K; Seto T; Takiguchi Y; Nishio M; Yoshioka H; Imamura F; Hotta K; Watanabe S; Goto K; Satouchi M; Kozuki T; Shukuya T; Nakagawa K; Mitsudomi T; Yamamoto N; Asakawa T; Asabe R; Tanaka T; Tamura T
Lancet; 2017 Jul; 390(10089):29-39. PubMed ID: 28501140
[TBL] [Abstract][Full Text] [Related]
11. Life-threatening hypertriglyceridemia-induced pancreatitis related to alectinib successfully treated by plasmapheresis: A review of the literature on metabolic toxicities associated with anaplastic lymphoma kinase inhibitors.
Rao A; Reddy A; Dinunno C; Elali I
J Oncol Pharm Pract; 2020 Sep; 26(6):1533-1537. PubMed ID: 32054410
[TBL] [Abstract][Full Text] [Related]
12. Acute kidney injury and long-term renal effects of alectinib in anaplastic lymphoma kinase-positive non-small cell lung carcinoma: a case report.
van Londen M; Roosma E; Vogels S; van Putten JWG; Janssen WMT
J Med Case Rep; 2022 Sep; 16(1):347. PubMed ID: 36176005
[TBL] [Abstract][Full Text] [Related]
13. A retrospective study of alectinib versus ceritinib in patients with advanced non-small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed.
Kuo CS; Tung PH; Huang AC; Wang CC; Chang JW; Liu CY; Chung FT; Fang YF; Guo YK; Yang CT
BMC Cancer; 2021 Mar; 21(1):309. PubMed ID: 33761908
[TBL] [Abstract][Full Text] [Related]
14. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
Peters S; Camidge DR; Shaw AT; Gadgeel S; Ahn JS; Kim DW; Ou SI; Pérol M; Dziadziuszko R; Rosell R; Zeaiter A; Mitry E; Golding S; Balas B; Noe J; Morcos PN; Mok T;
N Engl J Med; 2017 Aug; 377(9):829-838. PubMed ID: 28586279
[TBL] [Abstract][Full Text] [Related]
15. The use of alectinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer.
Gadgeel SM
Future Oncol; 2018 Aug; 14(18):1875-1882. PubMed ID: 29536761
[TBL] [Abstract][Full Text] [Related]
16. Revisiting a lower starting dose of alectinib in ALK-Positive non-small cell lung cancer.
Sacdalan DB; Lucero JA
Cancer Treat Res Commun; 2021; 27():100319. PubMed ID: 33515938
[TBL] [Abstract][Full Text] [Related]
17. Alectinib-Induced Severe Hemolytic Anemia in a Patient with ALK-Positive Non-Small Cell Lung Cancer: A Case Report.
Misawa K; Nakamichi S; Iida H; Nagano A; Mikami E; Tozuka T; Matsumoto M; Miyanaga A; Noro R; Kubota K; Yamaguchi H; Seike M
Onco Targets Ther; 2023; 16():65-69. PubMed ID: 36718244
[TBL] [Abstract][Full Text] [Related]
18. Cost Effectiveness of Alectinib vs. Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer.
Carlson JJ; Suh K; Orfanos P; Wong W
Pharmacoeconomics; 2018 Apr; 36(4):495-504. PubMed ID: 29488070
[TBL] [Abstract][Full Text] [Related]
19. Anaplastic Lymphoma Kinase Mutation-Positive Non-Small Cell Lung Cancer.
Serritella AV; Bestvina CM
Thorac Surg Clin; 2020 May; 30(2):137-146. PubMed ID: 32327172
[TBL] [Abstract][Full Text] [Related]
20. Alectinib-induced Immune Hemolytic Anemia in a Patient with Lung Adenocarcinoma.
Okumoto J; Sakamoto S; Masuda T; Yamaguchi K; Horimasu Y; Miyamoto S; Nakashima T; Iwamoto H; Fukushima N; Fujitaka K; Hamada H; Hattori N
Intern Med; 2021 Feb; 60(4):611-615. PubMed ID: 32999219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]